 Survival Analysis
"Survival Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
| Descriptor ID |
D016019
|
| MeSH Number(s) |
E05.318.740.998 N05.715.360.750.795 N06.850.520.830.998
|
| Concept/Terms |
Survival Analysis- Survival Analysis
- Analysis, Survival
- Analyses, Survival
- Survival Analyses
|
Below are MeSH descriptors whose meaning is more general than "Survival Analysis".
Below are MeSH descriptors whose meaning is more specific than "Survival Analysis".
This graph shows the total number of publications written about "Survival Analysis" by people in this website by year, and whether "Survival Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 0 | 1 | 1 | | 1990 | 0 | 12 | 12 | | 1991 | 0 | 8 | 8 | | 1992 | 0 | 9 | 9 | | 1993 | 0 | 9 | 9 | | 1994 | 0 | 12 | 12 | | 1995 | 2 | 12 | 14 | | 1996 | 1 | 16 | 17 | | 1997 | 1 | 17 | 18 | | 1998 | 0 | 17 | 17 | | 1999 | 0 | 31 | 31 | | 2000 | 1 | 33 | 34 | | 2001 | 0 | 32 | 32 | | 2002 | 1 | 35 | 36 | | 2003 | 0 | 51 | 51 | | 2004 | 0 | 56 | 56 | | 2005 | 1 | 51 | 52 | | 2006 | 0 | 60 | 60 | | 2007 | 0 | 46 | 46 | | 2008 | 2 | 43 | 45 | | 2009 | 0 | 47 | 47 | | 2010 | 1 | 44 | 45 | | 2011 | 2 | 41 | 43 | | 2012 | 0 | 42 | 42 | | 2013 | 0 | 27 | 27 | | 2014 | 0 | 41 | 41 | | 2015 | 0 | 36 | 36 | | 2016 | 1 | 40 | 41 | | 2017 | 3 | 51 | 54 | | 2018 | 3 | 44 | 47 | | 2019 | 0 | 27 | 27 | | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Survival Analysis" by people in Profiles.
-
Thalji SZ, Tsai S, Gamblin TC, Clarke C, Christians K, Charlson J, Ethun CG, Poultsides G, Grignol VP, Roggin KK, Votanopoulos K, Fields RC, Abbott DE, Cardona K, Mogal H. Outcomes of palliative-intent surgery in retroperitoneal sarcoma-Results from the US Sarcoma Collaborative. J Surg Oncol. 2020 Jun; 121(7):1140-1147.
-
Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, Maloy M, Clurman AG, Stein-Thoeringer CK, Markey KA, Docampo MD, Burgos da Silva M, Khan N, Gessner A, Messina JA, Romero K, Lew MV, Bush A, Bohannon L, Brereton DG, Fontana E, Amoretti LA, Wright RJ, Armijo GK, Shono Y, Sanchez-Escamilla M, Castillo Flores N, Alarcon Tomas A, Lin RJ, Yáñez San Segundo L, Shah GL, Cho C, Scordo M, Politikos I, Hayasaka K, Hasegawa Y, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Jenq RR, Teshima T, Chao NJ, Holler E, Xavier JB, Pamer EG, van den Brink MRM. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020 02 27; 382(9):822-834.
-
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 01 11; 395(10218):132-141.
-
Parker WF, Anderson AS, Gibbons RD, Garrity ER, Ross LF, Huang ES, Churpek MM. Association of Transplant Center With Survival Benefit Among Adults Undergoing Heart Transplant in the United States. JAMA. 2019 11 12; 322(18):1789-1798.
-
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
-
Gaudet D, Durst R, Lepor N, Bakker-Arkema R, Bisgaier C, Masson L, Golden L, Kastelein JJ, Hegele RA, Stein E. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Am J Cardiol. 2019 12 15; 124(12):1876-1880.
-
Parks J, Vasileiou G, Parreco J, Pust GD, Rattan R, Zakrison T, Namias N, Yeh DD. Validating the ATLS Shock Classification for Predicting Death, Transfusion, or Urgent Intervention. J Surg Res. 2020 01; 245:163-167.
-
Newman NB, Brett CL, Kluwe CA, Patel CG, Attia A, Osmundson EC, Kachnic LA. Immortal Time Bias in National Cancer Database Studies. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):5-12.
-
Madariaga MLL, Geller A, Lanuti M, Ott H, Allan JS, Donahue DM, Mathisen DJ, Wright CD, Gaissert HA. Pulmonary Artery Resection During Lung Resection for Malignancy. Ann Thorac Surg. 2019 12; 108(6):1692-1700.
-
Patel SS, Pinkus GS, Ritterhouse LL, Segal JP, Dal Cin P, Restrepo T, Harris MH, Stone RM, Hasserjian RP, Weinberg OK. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019 08; 94(8):921-928.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|